drugset / Trial / NCT01589380
A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)
Phase 4
Unknown
100 enrolled
Seoul National University Hospital
Boryung Pharmaceutical Co., Ltd · collabChonnam National University Hospital · collabKorea University Anam Hospital · collabKorea University Guro Hospital · collabSamsung Medical Center · collabSeoul National University Bundang Hospital · collabSeverance Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
We hypothesized that fimasartan, a new generation ARBs, would improve exercise capacity and decrease the rate of progression of AS by modifying hemodynamic factors and reducing adverse LV remodeling favorably in patients with asymptomatic moderate to severe AS.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-05
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fimasartan | Small molecule | 30 mg | — |
| Comparator | Fimasartan | Small molecule | 60 mg | — |